> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# GoodRx Misses Quarterly Filing Deadline As Earlier Revenue Needs Upward Corrections
- URL: https://www.bullished.co/goodrx-misses-quarterly-filing-deadline-as-earlier-revenue-needs-upward-corrections-7749cc0f/
- Published: 2026-11-10T11:21:45.000Z
- Updated: 2026-11-10T11:21:45.000Z
- Description: The company expects no significant year-over-year change in results and plans to file within the five-calendar-day grace period.
- Author: Matteo Parrino
- Tags: SEC Filings, GDRX, Industry: Healthcare

[GoodRx](https://www.bullished.co/tag/gdrx/), which helps Americans find lower prescription-drug prices, delayed its quarterly report Tuesday because corrections to earlier accounts and a review of financial-reporting controls remain unfinished. The company said in its SEC late-filing notice that those corrections also affect the statements needed for its third-quarter report.

## More Revenue, Revised Profits

The accounting review concerns Pharma Direct transactions whose revenue belonged in earlier periods. GoodRx recorded too little revenue in both the first and second quarters, and its preliminary corrections would increase profits as well.

GoodRx's audit and risk committee decided on October 27 that investors should [stop relying](https://www.sec.gov/Archives/edgar/data/0001809519/000180951926000184/gdrx-20261027.htm?ref=bullished.co) on those quarterly accounts, the company said in an 8-K filed Monday, November 2\. The warning also covers earnings releases, presentations and other communications describing the affected financial results.

Its preliminary estimates put first-half revenue at $424.2 million, versus the previously reported $394.4 million. First-half net income would rise to $24.6 million from $9.7 million, while operating income would increase to $57.8 million from $37.6 million.

The larger quarterly revenue adjustment falls in the second quarter: GoodRx expects to add [$22.3 million](https://www.sec.gov/Archives/edgar/data/0001809519/000180951926000184/gdrx-20261027.htm?ref=bullished.co) to both Pharma Direct revenue and total revenue. The first-quarter adjustment would add $7.5 million to each. All those estimates remain preliminary and could change as the review and restatements proceed.

## Pharma Direct And Accounting Controls

Pharma Direct sells advertising and savings programs to drugmakers. GoodRx's main business earns money from pharmacy benefit managers and partner pharmacies when consumers fill prescriptions using its discount codes; it also sells Gold subscriptions offering lower prices, mail delivery and telehealth visits.

The company is still assessing how the restatements affect its financial-reporting controls. It [expects serious weaknesses](https://www.sec.gov/Archives/edgar/data/0001809519/000180951926000192/gdrx-formnt10xq12bx25xq3fi.htm?ref=bullished.co) — known as material weaknesses — in those controls for the affected periods and at the end of September.

GoodRx plans to correct the earlier accounts through amended quarterly reports. Errors in the statements covering three months and nine months through September 30, 2026, are holding up the quarterly report.

## A Five-Day Filing Plan

GoodRx said it does not expect a significant change in operating results from the corresponding year-earlier period. That expectation comes from the late-filing notice, rather than a completed third-quarter earnings report.

The company checked the notice's commitment to file its quarterly report by the fifth calendar day after the prescribed due date. It also plans to release third-quarter earnings within that window, which Rule 12b-25 provides for late quarterly filings.

GoodRx's next planned step is to publish third-quarter results and submit the quarterly report within that five-calendar-day window.

Learn

- [What Happens When A Stock You Own Is Delisted →](https://www.bullished.co/learn/what-happens-when-stock-delisted-you-own-it/)  
If a stock you own is delisted, you usually still own the shares. Learn what Item 3.01 notices mean, acquisition vs compliance delistings, and how to check.

### Sources

- [Form NT 10-Q — GoodRx Holdings, Inc. (GDRX)](https://www.sec.gov/Archives/edgar/data/0001809519/000180951926000192/gdrx-formnt10xq12bx25xq3fi.htm?ref=bullished.co) — SEC EDGAR
- [8-K Filing — GoodRx Holdings, Inc., filed 2026-11-02 (Items 4.02)](https://www.sec.gov/Archives/edgar/data/0001809519/000180951926000184/gdrx-20261027.htm?ref=bullished.co) — SEC EDGAR

### More on GoodRx

- [GoodRx Says Revenue For Two 2026 Quarters Was Understated By $29.77 Million](https://www.bullished.co/goodrx-says-revenue-for-two-2026-quarters-was-understated-by-29-77-million-0eea5a4a/)

[All GoodRx (GDRX) coverage →](https://www.bullished.co/tag/gdrx/)